<?xml version="1.0" encoding="UTF-8"?>
<p id="p0180">The viral-induced myositis proposed owing to the abundance cases manifesting with myalgia and a raised serum CK level. In one cohort research encompassed SARS cases, ascertained that more than 60% of the cases presented with myalgia and muscular disturbance on the initial consultation, a different study reported 30% of the SARS cases had raised serum CK levels with myopathy exhibiting with significant myofiber atrophy particularly for cases in whom hydrocortisone administered. Never the less, in a most recent prospective case analysis of the SARS-CoV-2 confirmed cases, 44% myalgia or fatigue reported; future studies expected to explore whether this is a feature of viral effected myositis like previous ECoV 
 <xref rid="b0170" ref-type="bibr">[34]</xref>, 
 <xref rid="b0315" ref-type="bibr">[63]</xref>, 
 <xref rid="b0320" ref-type="bibr">[64]</xref>.
</p>
